Drugs company questions patent pool concept
07 December 2009
|
Emma Barraclough, Brussels
A lawyer for one of the world’s biggest pharmaceutical companies has said that pooling patents over drugs will not solve the major problems of access to medicines
Speaking at the Competition 2009 conference in Brussels on Friday, Stéphane Drouin, head of European patents at Pfizer, said that IP is not a major issue when it comes to accessing drugs in least developed countries.
Only subscribers have complete access to Managing IP,
log in or
subscribe now.
Alternatively take a
free trial, giving you seven days access to Managing IP and regular newsletters for the international IP community, and US and Canadian practitioners specifically.
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial